According to an investigation in JAMA, individuals who developed respiratory failure after being infected with severe 2009 H1N1 influenza, and who received treatment with a system that adds oxygen to their blood, had a lower rate of dying in hospital compared to those who did not receive the treatment.

The investigation is being published early online to accompany its presentation at the European Society of Intensive Care Medicine meeting being held in Berlin.

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reported dramatically improved antiviral efficacy with its optimized FluCide™ drug candidates in its most recent animal study. In the influenza mouse lethal infection model, animals treated with one of the optimized FluCide™ nanoviricide drug candidates survived beyond the stated full duration of study (21 days), and those treated with two additional drug candidates survived almost the full duration of the study. Animals in these three groups survived significantly longer (20.2 to 22.2 days) as compared to the animals treated with Oseltamivir (Tamiflu®; only 8.3 days).

On November 19, Jason Martin returned to the Medical Intensive Care Unit (MICU) at Vanderbilt University Medical Center for the first time since he nearly died there during last year's H1N1 flu pandemic. The tall and burly Warren County, TN, ambulance worker - a 30-year-old, father of three young children - broke down and hugged some of the nurses he recognized.

"I got sick on September 12 and didn't come out of it for the next 20 days. I am just so grateful I came through," Martin said, wiping his eyes.

During the Flu epidemic A/H1N1 in 2009, the trends published by Cegedim Strategic Data (CSD) through the use of their Longitudinal Patient Database (LPD) concerning seasonal influenza, Flu A/H1N1, and flu-like syndrome aligned closely with those published by governmental institutions (Sentinelles Network). The LPD peak trends of flu-related diagnoses were slightly in advance compared to those of the Sentinelles Network.

Approximately 183 million Americans, or 59% of the country's population are thought to be immune to the H1N1 virus that caused a pandemic in 2009, according to estimates by scientists at the National Institute of Allergy and Infectious Diseases, part of the NIH (National Institutes of Health). They are also attempting to speculate where *pH1N1 will go from here by reviewing the fate of some that took place in history.

The 2009 A(H1N1) swine flu pandemic caused a higher incidence of neurological complications - especially seizures and encephalopathy (brain malfunction or damage) - in children than normal seasonal flu, scientists from the University of Utah, Clinical Neurosciences Center revealed in an article published in Annals of Neurology.

Fears over the influenza A virus (H1N1; sometimes referred to as swine flu) have motivated researchers to investigate the antimicrobial activity of the Aganocide® compounds against viruses. In a study presented at this year's Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), a team led by Professor Markus Nagl, MD of Medical University of Innsbruck and including D. Debabov, PhD and K. Hybiske, PhD of NovaBay Pharmaceuticals evaluated the in vitro virucidal activity of three compounds: N-chlorotaurine (NCT), a compound produced by human phagocytes; and two NCT analogs, NVC-612 and NVC-422.